Heterogeneity of immune checkpoint inhibitor-related inflammatory central nervous system adverse event reporting signals in primary and metastatic brain tumors: a pharmacovigilance study with single-cell and spatial transcriptomic contextualization - Takeaways - MDSpire

Heterogeneity of immune checkpoint inhibitor-related inflammatory central nervous system adverse event reporting signals in primary and metastatic brain tumors: a pharmacovigilance study with single-cell and spatial transcriptomic contextualization

  • By

  • Junlin Song

  • Zeyu He

  • Chong Han

  • Xiaohong Hou

  • July 8, 2026

  • 0 min

Share

  • 1

    Immune checkpoint inhibitors can induce severe inflammatory central nervous system adverse events, though they are uncommon.

  • 2

    The study analyzed inflammatory CNS irAE reporting signals across primary CNS tumors, brain metastases, and non-CNS solid tumors.

  • 3

    Adjusted odds ratios indicated tumor phenotype-associated heterogeneity in inflammatory CNS irAE reporting signals.

  • 4

    Single-cell analyses localized strict inflammatory module activity primarily to myeloid and T/NK compartments.

  • 5

    The findings suggest that stricter phenotype definitions are more specific than broader neuroinflammatory definitions.

Original Source(s)

Heterogeneity of immune checkpoint inhibitor-related inflammatory central nervous system adverse event reporting signals in primary and metastatic brain tumors: a pharmacovigilance study with single-cell and spatial transcriptomic contextualization

  • by Junlin Song, Zeyu He, Chong Han, Xiaohong Hou

  • July 8, 2026

Related Content

Post-endoscopy gastric cancer in Latin America: a multicentre cohort study from Colombia

Innovative use of therapeutic antibodies in lung cancer: the current landscape of ADCs and other antibody-based therapies

CGRP: the immune system’s double agent – context-dependent roles in inflammation, resolution and cancer